Type 2 & other diabetes

Feasibility, Acceptability, and Validity of Home Continuous Glucose Monitoring–Based Oral Glucose Tolerance Test in Youth

J Clin Endocrinol MetabPublished Prospective observational study

Authors' conclusion

Home-OGTT was acceptable, but strategies to precisely capture glucose ingestion timing could improve feasibility. Alternate dysglycemia thresholds may need to be defined prior to using CGM as a method for T2D screening in youth.

Study context

Population
Youth aged 8 to 18 years with overweight/obesity and prediabetes-range hemoglobin A1c (HbA1c), fasting glucose or 2-hour glucose on oral glucose tolerance test (OGTT), and/or ≥1 guideline-based T2D risk factors; pediatric clinical and translational research center30 with valid home-OGTT data
Participants
39 participants
Exposure
Home continuous glucose monitoring (CGM)-based OGTT vs research-center serum OGTT
Outcome
Feasibility (% with valid home-OGTT data), acceptability (survey and interview responses) and validity (sensitivity, specificity, PPV, NPV of home- vs research-OGTT dysglycemia: fasting ≥100 mg/dL; 2-hour ≥140 mg/dL)
Methodological detailssingle-centre, blinded CGM
  • Single-centre
  • Blinded CGM

Main finding

As reported in the abstract

Feasibility, acceptability and validity of home-OGTT
GroupSpecificity, fastingSpecificity, 2-hourPPV, fastingPPV, 2-hourSensitivity and NPV
Home-OGTT10%25%3.6%18.2%≥80%

Home-OGTT

Specificity, fasting10%
Specificity, 2-hour25%
PPV, fasting3.6%
PPV, 2-hour18.2%
Sensitivity and NPV≥80%
Valid home-OGTT data (feasibility)
30 (77%)
Acceptability excellent/great
92%
Acceptability neutral
8%

Observational data: associations, not effects.

Original publication

Feasibility, Acceptability, and Validity of Home Continuous Glucose Monitoring–Based Oral Glucose Tolerance Test in Youth. J Clin Endocrinol Metab. Published 6 December 2024. doi:10.1210/clinem/dgae845

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.